Retatrutide Safety Overview

There are no reported deaths directly attributed to retatrutide (Reta) in the available clinical trial data or published literature to date. The main risks associated with retatrutide involve gastrointestinal side effects (such as severe diarrhea), dehydration, and rare class-level concerns like pancreatitis or gallbladder disease, but the evidence does not document confirmed fatal outcomes specific to retatrutide at this timeEfficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

Like other GLP-1-based agents, serious complications could theoretically occur—particularly in high-risk or medically complex populations—but the published corpus and safety reporting do not identify retatrutide-specific mortality. Ongoing and future studies will further clarify the safety profile as larger populations are followed.

Were you interested in specific side effect patterns or warnings from real-world use?